Blindspot Capital
In this episode, healthcare investor and strategist Maryann Umoren Selfe is joined by Matthias Wipf, CEO of Swiss medtech company MOMM Diagnostics, to examine the systemic gaps in how we identify and fund life-saving healthcare infrastructure for women.
🟣 Why preeclampsia remains one of the most dangerous, misunderstood pregnancy complications
🟣 What point-of-care diagnostics like Pre-Exclude are doing differently
🟣 Why diagnostics in women’s health are underfunded and what that reveals about investor psychology
🟣 How preeclampsia connects to long-term cardiovascular risk 🟣 What’s holding back innovation in maternal health and how to change it
🟣 Why investing in maternal health benefits not just women, but entire health systems
Join 10,000+ readers of the FemmeHealth newsletter on Substack.
------------------
About MOMM Diagnostics:Founded in 2018, MOMM Diagnostics is reimagining maternal care with préXclude, a breakthrough test for early detection of preeclampsia. With just a drop of blood and a few minutes, their technology gives clinicians the power to act before pregnancy complications become emergencies. Born out of research collaborations in Switzerland and California, MOMM is part of a new wave of founders who are turning overlooked health problems into high-impact innovation. Learn more here.